ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A580

Its studies are led by HUTCHMED.

Furthest: phase 2, since Feb 1, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED11 open or runningphase 2since Feb 1, 2026Feb 1, 2026Dec 31, 2028phase 2 · NCT07396584

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 1, 2026First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07396584 · 186 planned · United States, China

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07396584

TargetBeta

EGFR →read by rule
“An antibody-targeted therapy conjugate (ATTC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the receptor tyrosine kinase human epidermal growth factor receptor (EGFR) ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07396584Solid Tumors, Adult · United States, China2RecruitingDec 31, 2028186

How it is read

Names in the registry

  • “HMPL-A580”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.